Clinical trials: Squamous Cell Cancer
Non-squamous Non-small Cell Lung Cancer
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
This trial is a multicenter, open-label, Phase II clinical study to explore the efficacy and safety of BL-M07D1 in combination with pembrolizumab in patients with locally advanced or metastatic HER2-overexpressing non-squamous…
- Trial name
- NCT07264816
- Testing
- BL-M07D1, Pembrolizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cervical Cancer, Anal Cancer
Detecting HPV DNA in Anal and Cervical Cancers
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer.
- Conditions
- Cervical Cancer, Anal Cancer, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Cervical Carcinoma
- Trial name
- NCT04857528
- Testing
- Radiation Treatment With or Without Chemotherapy, Blood Sample Collection, HPV Genotyping (HPV DNA Test)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Non-Squamous Non-small Cell Lung Cancer
Phase 3 Clinical Study of AK112 for NSCLC Patients
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer…
- Trial name
- NCT05184712
- Testing
- Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 322 people
- Sponsor
- Akeso
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and…
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage IV
- Trial name
- NCT05526924
- Testing
- Chemoradiation, Pamiparib, Hydroxyurea
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
This phase Ib trial tests the safety, side effects and best dose of tumor membrane vesicle (TMV) vaccine therapy alone and in combination with pembrolizumab and evaluates how well it works in treating patients with head and neck…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT06868433
- Testing
- Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Squamous Cell Cancer of Head and Neck (SCCHN)
Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer
This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer
- Trial name
- RTL-DART (NCT07348887)
- Testing
- Daily adaptive radiation therapy, Image guided radiation therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT
This study aims to evaluate the role of early response assessment by 18F-FDG PET/CT in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma with PD-L1 CPS >1 treated with pembrolizumab…
- Trial name
- PEMBRO-PET (NCT07448727)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Rome Tor Vergata
HPV-Related Squamous Cell Carcinoma
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
To determine if it is feasible to use neoadjuvant immunotherapy (or immunotherapy plus chemotherapy) to reduce treatment intensity and improve long-term quality of life while maintaining very high cure rates.
- Trial name
- MINIMA (NCT04988074)
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Atypical Squamous Cell of Undetermined Significance, ASC-US
Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population
This study compares the efficacy of cytology (Pap smear) with the molecular screening in their ability to detect reactive cellular changes in the cervix among an open population
- Conditions
- Atypical Squamous Cell of Undetermined Significance, ASC-US, Atypical Glandular Cells of Uncertain Significance, AGUS
- Trial name
- NCT07211204
- Testing
- Physical examination, Liquid-based cytology, Molecular screening
- Where
- Mexico
- Volunteers
- healthy volunteers welcome
- Sponsor
- Timser SAPI de CV
Squamous Cell Lung Cancer
An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer
This single-arm, open-label, multicenter, Phase I study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK)/pharmacodynamics (PD), biomarker, and immunogenicity of C-CAR031 in adult participants…
- Trial name
- NCT07444281
- Testing
- C-CAR031
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai AbelZeta Ltd.
Advanced Esophageal Squamous Cell Carcinoma
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Safety and Efficacy of Anlotinib Hydrochloride Combined with Benmelstobart versus Toripalimab Combined with Chemotherapy as…
- Trial name
- NCT07446335
- Testing
- anlotinib combined with benmelstobart, Toripalimab Combined with Chemotherapy
- Where
- China
- Volunteers
- 578 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Head and Neck Cancer, Radiotherapy
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at a locally advanced stage, where cisplatin-based chemoradiotherapy is standard but still results in high recurrence rates.
- Conditions
- Head and Neck Cancer, Radiotherapy, Anti-PD-1/CTLA-4 Antibody
- Trial name
- NCT07447570
- Testing
- Iparomlimab and Tuvonralimab injection, Hypofractionated Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Squamous Cell Carcinoma of the Head and Neck
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC) patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be resistant to standard Radiation Therapy…
- Trial name
- NCT02031250
- Testing
- Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation Therapy)
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- University of Michigan Rogel Cancer Center
Suspected or Known Squamous Cell Neoplasia, Prior History of Squamous Cell Dysplasia and /or Neoplasia
Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States
In a previous clinical trial in China and the United States (US), the investigators developed and validated a mobile, high-resolution microendoscope (mHRME) for screening and surveillance of esophageal squamous cell neoplasia…
- Trial name
- NCT06435286
- Testing
- Proflavine Hemisulfate, Artificial Intelligence Mobile High-Resolution Microendoscope
- Where
- 4 sites in United States, Brazil
- Volunteers
- 200 people
- Sponsor
- Baylor College of Medicine
Head and Neck Cancer
Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver tumor-killing substances to…
- Trial name
- NCT00003809
- Testing
- cetuximab, cisplatin
- Where
- 76 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Head and Neck Squamous Cell Carcinoma
Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer
This study will investigate the clinical validity and clinical utility of the OncoPrism-HNSCC (Head and Neck Squamous Cell Carcinoma) test.
- Trial name
- PREDAPT-HNSCC2 (NCT05296135)
- Testing
- OncoPrism-HNSCC™
- Where
- United States
- Sponsor
- Cofactor Genomics, Inc.
Esophageal Cancer
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
This trial is conducted in patients with unresectable locally advanced esophageal squamous cell carcinoma. The investigators plan to enroll 60 patients with unresectable locally advanced esophageal cancer in Tianjin cancer…
- Trial name
- NCT06452602
- Testing
- Induction immunochemotherapy followed by Adebrelimab plus concurrent chemoradiotherapy, Induction immunochemotherapy followed by concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Cervical Cancer, Squamous Cell Carcinoma of Cervix
Intra-lesional Tumor Boost for Bulky Cervical Cancer
The goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment.
- Trial name
- INTLECTUAL (NCT07435376)
- Testing
- intra-lesional boost IMRT, High Dose Rate Brachytherapy
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Bundang Hospital
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This study aims to investigate the safety and efficacy of oral paclitaxel combined with radiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT07435454
- Testing
- oral paclitaxel+radiotherapy
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangsu Cancer Institute & Hospital